163 related articles for article (PubMed ID: 16990957)
1. Should high sensitive C-reactive protein measurement be included in health screening packages?
Hawkins RC; Leong L
Singapore Med J; 2006 Oct; 47(10):837-40. PubMed ID: 16990957
[TBL] [Abstract][Full Text] [Related]
2. Level of high-sensitivity C-reactive protein in Saudi patients with chronic stable coronary artery disease.
Habib SS
J Ayub Med Coll Abbottabad; 2008; 20(2):3-6. PubMed ID: 19385446
[TBL] [Abstract][Full Text] [Related]
3. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population.
Duprez DA; Somasundaram PE; Sigurdsson G; Hoke L; Florea N; Cohn JN
J Hum Hypertens; 2005 Jul; 19(7):515-9. PubMed ID: 15905893
[TBL] [Abstract][Full Text] [Related]
4. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
Sellmayer A; Limmert T; Hoffmann U
Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
[TBL] [Abstract][Full Text] [Related]
5. Health screening packages: the place of measuring C-reactive protein.
Wong MS
Singapore Med J; 2006 Oct; 47(10):827-9. PubMed ID: 16990955
[No Abstract] [Full Text] [Related]
6. Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease.
Huang PH; Lu TM; Wu TC; Lin FY; Chen YH; Chen JW; Lin SJ
Coron Artery Dis; 2008 May; 19(3):187-93. PubMed ID: 18418236
[TBL] [Abstract][Full Text] [Related]
7. Inflammation in atherothrombosis: how to use high-sensitivity C-reactive protein (hsCRP) in clinical practice.
Ridker PM
Am Heart Hosp J; 2004; 2(4 Suppl 1):4-9. PubMed ID: 15539969
[TBL] [Abstract][Full Text] [Related]
8. Reduction in C-reactive protein through cardiac rehabilitation and exercise training.
Milani RV; Lavie CJ; Mehra MR
J Am Coll Cardiol; 2004 Mar; 43(6):1056-61. PubMed ID: 15028366
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity C-reactive protein is associated with the risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.
Otsuka T; Kawada T; Katsumata M; Ibuki C; Kusama Y
Int J Cardiol; 2008 Sep; 129(2):245-50. PubMed ID: 17997174
[TBL] [Abstract][Full Text] [Related]
10. Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.
Woloshin S; Schwartz LM; Kerin K; Welch HG
J Gen Intern Med; 2007 Feb; 22(2):197-204. PubMed ID: 17356986
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of plasma high sensitive C-reactive protein in detecting three-vessel coronary artery disease: modification by apolipoprotein E genotype.
Mennander A; Kuukasjärvi P; Laurikka J; Nikus K; Karhunen PJ; Tarkka M; Lehtimäki T
Scand J Clin Lab Invest; 2008; 68(8):714-9. PubMed ID: 18609102
[TBL] [Abstract][Full Text] [Related]
12. Rationale for targeted rather than population based screening with C-reactive protein using the National Health and Nutrition Examination Survey (1999 to 2002).
Guttormsen BN; Stein JH; McBride PE; Cullen MW; Gangnon R; Keevil JG
Am J Cardiol; 2007 Oct; 100(7):1130-3. PubMed ID: 17884376
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of C-reactive protein as a predictor of vascular risk.
Katrinchak C; Fritz K
J Am Acad Nurse Pract; 2007 Jul; 19(7):335-40. PubMed ID: 17680898
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
Morrow DA; de Lemos JA; Sabatine MS; Wiviott SD; Blazing MA; Shui A; Rifai N; Califf RM; Braunwald E
Circulation; 2006 Jul; 114(4):281-8. PubMed ID: 16847150
[TBL] [Abstract][Full Text] [Related]
15. Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus.
Nikpour M; Gladman DD; Ibañez D; Urowitz MB
Lupus; 2009 Oct; 18(11):966-73. PubMed ID: 19762397
[TBL] [Abstract][Full Text] [Related]
16. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients--no additional power for mortality prediction with high-sensitivity CRP.
Grootendorst DC; de Jager DJ; Brandenburg VM; Boeschoten EW; Krediet RT; Dekker FW;
Nephrol Dial Transplant; 2007 Nov; 22(11):3277-84. PubMed ID: 17623721
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 4 expressions on peripheral blood monocytes were enhanced in coronary artery disease even in patients with low C-reactive protein.
Shiraki R; Inoue N; Kobayashi S; Ejiri J; Otsui K; Honjo T; Takahashi M; Hirata K; Yokoyama M; Kawashima S
Life Sci; 2006 Dec; 80(1):59-66. PubMed ID: 17045300
[TBL] [Abstract][Full Text] [Related]
18. [Prevalence of C-reactive protein levels in adult population in two regions in the czech republic and their relation to body composition].
Cerovská J; Hoskovcová P; Vosátková M; Zamrazilová H; Zamrazil V
Vnitr Lek; 2006 Nov; 52(11):1045-50. PubMed ID: 17165523
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
de Ferranti SD; Rifai N
Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
[TBL] [Abstract][Full Text] [Related]
20. C-reactive protein associated with coronary artery disease in Iranian patients with angiographically defined coronary artery disease.
Kazemi-Bajestani SM; Ghayour-Mobarhan M; Ebrahimi M; Moohebati M; Esmaeili HA; Ferns GA
Clin Lab; 2007; 53(1-2):49-56. PubMed ID: 17323825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
